Table 3

Effect of gender and various OCT features on duration of SRF resolution, final visual outcome and final CMT

Factors	Duration of SRF resolution (months)	P value*	Final LogMAR BCVA	P value*	Final CMT (μm)	P value*
Gender
Male (80)	2.46±1.45	0.04	0.20±0.18	0.14	221.96±15.92	0.10
Female (13)	3.76±2.04	0.04	0.28±0.18	0.14	214.30±15.22	0.10
HRDs
Yes (33)	3.48±1.90	0.001	0.31±0.19	<0.001	214.63±17.36	0.004
No (60)	2.18±1.20	0.001	0.16±0.15	<0.001	224.33±14.15	0.004
RPE bumps
Yes (28)	3.28±1.78	0.01	0.24±0.20	0.31	214.57±17.90	0.01
No (65)	2.36±1.45	0.01	0.20±0.17	0.31	223.61±14.36	0.01
PED
Yes (24)	2.95±1.68	0.27	0.21±0.20	0.97	221.95±15.81	0.70
No (69)	2.53±1.57	0.27	0.22±0.17	0.97	220.52±16.12	0.70
Fibrin
Yes (21)	3.00±1.84	0.25	0.24±0.17	0.45	217.23±17.54	0.23
No (72)	2.54±1.52	0.25	0.21±0.19	0.45	221.95±15.44	0.23

*Independent t-test.
BCVA, best-corrected visual acuity; CMT, central macular thickness; HRDs, hyper-reflective dots; OCT, optical coherence tomography; RPE, Retinal pigment epithelium; SRF, subretinal fluid .